World's Top 50 Companies in Neurology Devices in 2025 Watch List: Statistics Report (2024–2035)
RELEASE DATE: Aug 2025 Author: Spherical InsightsRequest Free Sample Speak to Analyst
Description
According to a research report published by Spherical Insights & Consulting, The Global Neurology Devices Market Size is projected To Grow from USD 18.1 Billion in 2024 to USD 41.2 Billion by 2035, at a CAGR of 8.57 % during the forecast period 2025–2035. The neurology devices market offers future opportunities through advancements in minimally invasive technologies, AI-integrated diagnostics, wearable monitoring devices, and rising demand for neurorehabilitation tools amid growing neurological disorder prevalence worldwide.
Introduction
The neurology devices market refers to the segment of medical technology focused on the diagnosis, monitoring, and treatment of neurological disorders such as epilepsy, Parkinson’s disease, Alzheimer’s, stroke, and traumatic brain injuries. These devices include neurostimulation systems, neurodiagnostic equipment, cerebral spinal fluid management devices, and interventional neurology tools. The market is driven by the rising global incidence of neurological disorders, the growing elderly population, and increasing awareness and early diagnosis efforts. Technological advancements such as AI-enabled brain mapping, minimally invasive surgical tools, and wearable neuro-monitoring devices are also fueling demand. Additionally, increasing healthcare spending and supportive regulatory frameworks contribute to market expansion.
Navigate Future Markets with Confidence: Insights from Spherical Insights LLP
The insights presented in this blog are derived from comprehensive market research conducted by Spherical Insights LLP, a trusted advisory partner to leading global enterprises. Backed by in-depth data analysis, expert forecasting, and industry-specific intelligence, our reports empower decision-makers to identify strategic growth opportunities in fast-evolving sectors. Clients seeking detailed market segmentation, competitive landscapes, regional outlooks, and future investment trends will find immense value in the full report. By leveraging our research, businesses can make informed decisions, gain a competitive edge, and stay ahead in the transition toward sustainable and profitable solutions.
Unlock exclusive market insights - Download The Brochure now and dive deeper into the future of the neurology devices market.
Neurology Devices Market Size & Statistics
- The Market Size for Neurology Devices was estimated To be worth USD 18.1 Billion in 2024.
- The Market Size is Going To expand at a CAGR of 8.57 % between 2025 and 2035.
- The Global Neurology Devices Market Size is anticipated to reach USD 41.2 Billion by 2035.
- North America is expected To Generate the highest demand during the forecast period in the Neurology Devices Market.
- Asia Pacific is expected to grow the fastest during the forecast period in the Neurology Devices Market.
Regional growth and demand
Asia Pacific is expected to grow the fastest during the forecast period in the neurology devices market. The Asia Pacific region is experiencing the quickest market expansion due to the substantial demand for medical services, coupled with a notable increase in funding directed towards research and development within the healthcare sector, as well as rising healthcare costs in developing nations like China and India
North America is expected to generate the highest demand during the forecast period in the neurology devices market. North America is leading the market with the highest market share during the forecast period due to strategic government initiatives and advanced healthcare infrastructure focused on brain tumor studies, pharmaceutical R&D, neuro science research and development, along with significant CNS research presence driving regional growth.
Top 5 Neurology Startups Impacting the Pharma Sector
1. APRINOIA Therapeutics – Tauopathy Diagnostics & Therapeutics
In certain neurodegenerative disorders, hyperphosphorylation of tau proteins results in the buildup of tangles within the brain. These neurofibrillary tangles (NFTs) are being studied for their contribution to Alzheimer’s disease (AD) and signs in various other neurological conditions. New MedTech and pharmaceutical startups are focusing on identifying NFTs and creating treatments to address brain dysfunction. APRINOIA Therapeutics, a startup from Taiwan, creates PET imaging tracers to identify NFT presence in the brain. The technology developed by the startup tracks the advancement of AD and tauopathies to facilitate early diagnosis and intervention for the conditions. Moreover, APRINOIA’s technology enables the creation of novel therapeutics for diseases by precisely evaluating the effectiveness of the development initiative. The startup also develops a repository of compounds that demonstrate therapeutic effectiveness against AD and tauopathies. The startup's pipeline features APN-1607 Tau PET Tracer, an imaging diagnostic tool that is presently undergoing Phase III clinical trials.
2. BIOTTS – Universal Transdermal Therapeutic System
Drug bioavailability is a vital measure in pharmacology that numerous research and development (R&D) teams strive to enhance. Medications that dissolve gradually in water or do not have adequate time for absorption decrease bioavailability and undermine the drug's intended effect. This motivates pharmaceutical startups to create innovative technologies that guarantee the drugs deliver the desired therapeutic effects. Polish startup BIOTTS develops its multi-transdermal carrier-Y (MTC-Y) platform to enhance bioavailability and reduce side effects. The MTC-Y carrier is a transdermal system designed for deep penetration, facilitating the delivery of hydrophilic substances, large molecules, and proteins through the skin. The startup utilizes its technology to provide the patent-pending MTC-A4 formulation, a topical anesthetic designed to enhance bioavailability and permeability at nerve endings in the skin's spinous layer. MTC-A4 is at present in the stage of preclinical trials.
3. Oxford Cannabinoid Technologies – Treating Neuroinflammatory Conditions
New pharmaceutical companies are investigating the involvement of the endocannabinoid system (ECS) in controlling sleep, emotions, hunger, memory, and reproduction. The ECS connects with various endocannabinoid receptors and includes enzymes that degrade the receptors once their task is finished. The ECS is presently associated with multiple bodily processes, such as pain regulation, inflammation, and functions of the skin and nerves, among others. Oxford Cannabinoid Technologies is a UK-based startup concentrating on developing drugs for applications in neurology, pain management, immunology, and cancer treatment. The startup's primary candidate, OCT461201, acts as a CB2 agonist, aimed at various neuroinflammatory disorders and autoimmune illnesses. OCT461201 is presently undergoing proof-of-concept (POC) studies for neuropathic pain and additional conditions.
4. GliaPharm – Targeting Glial Cells
Neuroglia, known as glial cells or simply glia, are non-neuronal cells in the central nervous system (CNS) that provide support and protection to neurons. Glia does not generate electrical signals and preserves system stability. A significant part of the human brain is made up of glia, which also outnumber the neurons. Pharma startups are exploring how neuroglial dysfunction contributes to different neurological diseases. GliaPharm is a Swiss startup focused on creating therapies aimed at glial cells for the treatment of neurological and psychiatric conditions. The company employs its unique drug development technology, GliaX, to enhance the neuroprotective function of glial cells. GliaPharm’s development program features a novel category of compounds that support cognitive abilities.
5. Disarm – Axonal Degeneration Treatment
Neurodegenerative disorders often have a direct relationship with the aging processes occurring in the nervous system. Axonal degeneration influences neuronal activities triggered by specific stimuli, including mechanical injury, defects in axonal transport, or chemotherapy medications. Emerging pharmaceutical firms concentrate on axonal functions since their degeneration happens long before the clinical signs of neurological diseases. This allows them to create preventive treatments to postpone the beginning of the neurodegenerative progression. The startup Disarm Therapeutics, located in the US, is focused on creating disease-modifying therapies for individuals with neurological disorders. Disarm employs its unique product engine to focus on SARM1, the key factor in axonal degeneration. The innovative SARM1 inhibitors from the startup aim to neutralize degenerative mechanisms like inflammation, intraocular pressure, trauma, and toxin production, among others.
Empower your strategic planning:
Stay informed with the latest industry insights and market trends to identify new opportunities and drive growth in the neurology devices market. To explore more in-depth trends, insights, and forecasts, please refer to our detailed report.
Top 10 Companies Leading the Neurology Devices Market
- Integra Lifesciences
- B.Braun SE
- Medtronic plc
- Natus Medical Inc
- Stryker Corporation
- Boston Scientific Corporation
- Abbott Laboratories
- LivaNova PLC
- Zimmer Biomet Holding Inc.
- Johnson & Johnson
1. Integra LifeSciences
Headquartered in Princeton, New Jersey, USA
Integra LifeSciences is a leading global medical technology company dedicated to regenerative medicine and neurosurgical solutions. The company develops, manufactures, and markets devices used in neurosurgery, orthopedic extremity surgery, and wound care. In neurology, it offers a range of tools for brain and spinal procedures, including cranial access kits, dural repair products, and monitoring systems. Known for innovation and clinical effectiveness, Integra collaborates closely with healthcare professionals to deliver solutions that improve patient outcomes. Its strategic acquisitions and consistent R&D investments continue to strengthen its position in the neurosurgical devices market.
2. B. Braun SE
Headquartered in Melsungen, Germany
B. Braun SE, is one of the world’s largest medical and pharmaceutical device companies. With a portfolio spanning across more than 5,000 healthcare products, the company is recognized for its expertise in neurocritical care and neurosurgical equipment. B. Braun’s neurology solutions include surgical instruments, infusion therapy devices, and products for intracranial pressure monitoring. The company emphasizes sustainability, safety, and patient well-being in all its innovations. Its strong global presence, comprehensive service networks, and focus on continuous medical education help B. Braun remain a trusted provider in the neurology device landscape.
3. Medtronic plc
Headquartered in Dublin, Ireland
Medtronic plc, is a global leader in medical technology, services, and solutions. The company offers an extensive neurology device portfolio, including deep brain stimulation systems, neurovascular products, and spinal cord stimulators. Medtronic’s innovations aim to improve patient lives by addressing chronic neurological conditions such as Parkinson’s disease, epilepsy, and stroke. With a strong focus on research and development, Medtronic continually pioneers cutting-edge technologies that transform patient care. Its global reach, strategic partnerships, and robust clinical data support its reputation as a key player in the neurology devices market.
4. Natus Medical Inc.
Headquartered in Middleton, Wisconsin, USA
Natus Medical Inc., is a prominent provider of medical devices and software for diagnosing and treating disorders affecting the brain, nerves, muscles, and sensory systems. The company specializes in neurodiagnostic and newborn care equipment, including EEG systems, EMG/NCV systems, and intracranial pressure monitoring devices. Natus focuses on improving neurological health through high-quality solutions backed by clinical expertise. Its commitment to education, training, and customer support, along with a legacy of innovation, makes it a preferred partner for hospitals and neurology clinics worldwide.
5. Stryker Corporation
Headquartered in Kalamazoo, Michigan, USA
Stryker Corporation is a global leader in medical technologies, including neurosurgical and spine systems. The company offers advanced tools for image-guided surgery, neurosurgical navigation, and cranial stabilization. With a focus on minimally invasive procedures and patient safety, Stryker’s neurology products support both acute and chronic neurological care. The company invests heavily in R&D and strategic acquisitions to enhance its capabilities in neurological innovation. Its comprehensive portfolio, customer-centric approach, and consistent technological improvements make Stryker a key contributor to the global neurology devices market.
Are you ready to discover more about the neurology devices market?
The report provides an in-depth analysis of the leading companies operating in the global neurology devices market. It includes a comparative assessment based on their product portfolios, business overviews, geographical footprint, strategic initiatives, market segment share, and SWOT analysis. Each company is profiled using a standardized format that includes:
Company Profiles
- Integra Lifesciences.
- Business Overview
- Company Snapshot
- Products Overview
- Company Market Share Analysis
- Company Coverage Portfolio
- Financial Analysis
- Recent Developments
- Merger and Acquisitions
- SWOT Analysis
- B.Braun SE
- Medtronic plc
- Natus Medical Inc
- Stryker Corporation
- Boston Scientific Corporation
- Abbott Laboratories
- LivaNova PLC
- Zimmer Biomet Holding Inc.
- Johnson & Johnson
Conclusion
The neurology devices market is undergoing a transformative shift driven by advancements in technology, increasing neurological disorder prevalence, and rising demand for early diagnosis and effective treatment solutions. With growing investment in research and development, as well as the emergence of innovative startups, the landscape is evolving rapidly to meet clinical needs. Major players are focusing on expanding their product portfolios, enhancing patient outcomes, and leveraging AI and minimally invasive solutions. As regional markets like Asia Pacific gain momentum and North America maintains strong demand, stakeholders across the industry are poised to capitalize on long-term growth and innovation opportunities.
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?